Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model

@inproceedings{Marsousi2014PredictionOM,
  title={Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model},
  author={Niloufar Marsousi and Youssef Daali and Serge L. Rudaz and Lisa Almond and Holly Humphries and Jules Alexandre Desmeules and Caroline Flora Samer},
  booktitle={CPT: pharmacometrics & systems pharmacology},
  year={2014}
}
Evaluation of a potential risk of metabolic drug-drug interactions (DDI) is of high importance in the clinical setting. In this study, a physiologically based pharmacokinetic (PBPK) model was developed for oxycodone and its two primary metabolites, oxymorphone and noroxycodone, in order to assess different DDI scenarios using published in vitro and in vivo data. Once developed and refined, the model was able to simulate pharmacokinetics of the three compounds and the DDI extent in case of… CONTINUE READING